Is HLS Therapeutics a Can’t-Miss Buy?

HLS Therapeutics (TSX:HLS) has been surrounded by major announcements, but there’s only a little time to get in while you can.

| More on:
Pills spilling out of a prescription pot

Image source: Getty Images.

There have been several health stocks this year that have seen shares soar. The coronavirus may still be hitting the world fairly hard; however, Big Pharma has moved on. It’s all about finding the next big thing, and that could indeed be HLS Therapeutics (TSX:HLS). Today, I’m going to look at the recent activity surrounding HLS Therapeutics and discuss whether this could be a strong option for your portfolio. Even if you’re willing to only add a small stake for now.

Speaking of Big Pharma…

Let’s start out with the major announcement causing movement with HLS Therapeutics. In August, Pfizer announced it had made an agreement to “co-market” HLS’s cardiovascular drug Vascepa in Canada. Pfizer’s input puts significant value before the drug. Not only does it mean the company gets a thumbs-up from a now household name, but it should increase sales in a massive way.

Pfizer has a strong history of cross promotion, but chooses its targets wisely. This has occurred on several occasions during the last year, after the company announced an investment initiative. As of last month, HLS Therapeutics became another added to the list. The move puts Pfizer in the position to make sure this drug is a success, and that should see share performance benefit as a result.

The results

There are two sets of results I’d like to look at for Motley Fool investors to consider. First, there are the results announced before the major move. The company reported significant improvements with pandemic restrictions easing. Revenue was up 19% year over year during the second quarter, and adjusted EBITDA up 36% as well. There was already strong prescription growth for its Vascepa drug, up 41% with new patients and 44% with new prescribers. Revenue from the drug increased 42% from the quarter before. Further, gas from operations jumped to $8.9 million year to date — a 709% increase year over year! Of course, this is due in large part from the pandemic.

Shares of the company trade at $18.30 as of writing, an increase of 37% in the last year. However, Motley Fool investors still haven’t jumped on the stock, even with the major Pfizer news. That makes it a steal of a deal right now. HLS Therapeutics trades at a 2.8 P/B ratio and 25.2 EV/EBITDA, with analysts believing the stock will continue to “outperform” the market. In fact, the average one-year estimate is $31.29 — a 71% increase as of writing! With Pfizer now backing its Vascepa drug, HLS Therapeutics has a strong chance of reaching this average goal set out by analysts. Sales are set to double next year alone, with earnings per share set to triple by 2023.

Foolish takeaway

HLS Therapeutics looks like it could indeed be the next big winner among prescription drug makers. Motley Fool investors looking to get on pretty much the ground floor before a major boost would do well to consider the company. Shares have only increased a little this year, and by the end of October, that could change. The company will then announce its earnings report, and it’s likely to show even more sky-high growth surrounding this drug.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Coronavirus

Aircraft Mechanic checking jet engine of the airplane
Coronavirus

Air Canada Stock Fell 5% in November: Is it a Buy Today?

Air Canada (TSX:AC) stock saw remarkable improvements during its last quarter but still dropped 5% with more recession hints. So,…

Read more »

Airport and plane
Coronavirus

Is Air Canada Stock a Buy Today?

Airlines are on the rebound. Does Air Canada stock deserve to be on your buy list?

Read more »

A patient takes medicine out of a daily pill box.
Coronavirus

Retirees: 2 Healthcare Stocks That Could Help Set You up for Life

Healthcare stocks offer an incredible opportunity for growth for those investors who look to the right stocks, such as these…

Read more »

sad concerned deep in thought
Coronavirus

Here’s Why I Just Bought WELL Health Stock

WELL Health stock (TSX:WELL) may be a healthcare stock and a tech stock, but don't let that keep you from…

Read more »

healthcare pharma
Coronavirus

WELL Stock: The Safe Stock Investors Can’t Afford to Ignore

WELL stock (TSX:WELL) fell 68% from peak to trough, and yet there's no good reason as to why. So now…

Read more »

telehealth stocks
Tech Stocks

The Ultimate Growth Stock to Buy With $100 Right Now

After climbing 600%, this growth stock is now down 68%. But it won't be long before other investors catch on.

Read more »

consider the options
Coronavirus

Is Now the Perfect Time to Buy Cineplex Stock (TSX:CGX)?

Cineplex stock is significantly undervalued as it's shunned by investors. Yet, the business is showing great strength.

Read more »

A stock price graph showing declines
Dividend Stocks

Here’s Why I’m Confident About Investing Through the Down Market

There is no bear market in history that has not been followed by a bull cycle. Rather than fret over…

Read more »